Why the study?
Does candesartan reduce cardiovascular death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic heart failure patients with altered left ventricular systolic function?
Does candesartan reduce cardiovascular death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic heart failure patients with altered left ventricular systolic function?
Candesartan is an effective treatment for chronic heart failure with reduced ejection fraction, reducing mortality and hospitalizations when added to standard therapy or used as an alternative to ACE inhibitors.
May support candesartan in HFrEF; leaves open positioning versus ARNI or SGLT2i in contemporary regimens.
Candesartan cilexetil in the treatment of chronic heart failure Jean-Philippe Baguet, Gilles Barone-Rochette, Yannick NeuderDepartment of Cardiology, University Hospital, 38043 Grenoble, FranceAbstract: The prevalence of heart failure is ever increasing around the world, particularly due to aging populations. Despite improvements in treatment over the last 20 years, the prognosis for heart failure remains poor. Among the treatments recommended for chronic heart failure, angiotensin-converting enzyme (ACE) inhibitors and beta-blockers are crucial, provided of course that they are not contraindicated. However, angiotensin II receptor blockers (ARBs) can also be a beneficial treatment option. Candesartan is a particular ARB, characterized by a strong binding affinity to the angiotensin II type 1 receptor and slow dissociation. The benefits of candesartan have been demonstrated by the CHARM programme, which showed that candesartan significantly reduces the incidence of cardiovascular death, hospital admissions for decompensated heart failure, and all-cause mortality in chronic heart failure patients with altered left ventricular systolic function, when added to standard therapies or as an alternative to ACE inhibitors when these are poorly tolerated. Furthermore, candesartan can protect against myocardial infarction, atrial fibrillation and diabetes. Tolerance to candesartan is good, but blood pressure and serum potassium and creatinine levels must be monitored.
No takes yet. Share an insight, caveat, or question.
Jean-Philippe Baguet (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: